Last reviewed · How we verify
pPJV7630 administered by PMED
At a glance
| Generic name | pPJV7630 administered by PMED |
|---|---|
| Sponsor | PowderMed |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects (PHASE1)
- Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pPJV7630 administered by PMED CI brief — competitive landscape report
- pPJV7630 administered by PMED updates RSS · CI watch RSS
- PowderMed portfolio CI